Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Unity Biotechnology, Inc. (UBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., August 8, 2023 --"
08/03/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 SC 13G/A FMR LLC reports a 4% stake in UNITY BIOTECHNOLOGY INC
05/09/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., May 9, 2023 --"
05/03/2023 144 Form 144 - Report of proposed sale of securities:
05/02/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 8-K Quarterly results
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023",
"4 0 2 4 8 12 16 20 24 28 32 36 40 44 48"
03/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC",
"Amendment No. 2 to Sales Agreement, by and between Unity Biotechnology, Inc. and Cowen and Company, LLC"
03/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates SOUTH SAN FRANCISCO, Calif., March 15, 2023 --"
02/14/2023 SC 13G Alyeska Investment Group, L.P. reports a 10% stake in Unity Biotechnology, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 9.2% stake in UNITY BIOTECHNOLOGY INC
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study in wet Age-Related Macular Degeneration Expected in First Quarter of 2023 - - As of September 30, 2022, UNITY had approximately $103.9 million in cash, cash equivalents and marketable securities, providing runway into the first quarter of 2024 - SOUTH SAN FRANCISCO, Calif., November 8, 2022 --"
11/01/2022 8-K Quarterly results
10/25/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/25/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/19/2022 8-K Quarterly results
10/14/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
10/11/2022 SC 13G/A FMR LLC reports a 9.7% stake in UNITY BIOTECHNOLOGY INC
09/13/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/12/2022 SC 13G/A FMR LLC reports a 15% stake in UNITY BIOTECHNOLOGY INC
08/30/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Unity Biotechnology, Inc. and SVB Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the underwriters named therein",
"Form of Warrant",
"Opinion of Latham & Watkins LLP",
"UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering"
08/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/19/2022 8-K Quarterly results
08/19/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy